Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ICLR
vs
S&P 500
ICLR
S&P 500
Over the past 12 months, ICLR has underperformed S&P 500, delivering a return of +3% compared to S&P 500's +13% growth.
Stocks Performance
ICLR vs S&P 500
Performance Gap
ICLR vs S&P 500
Performance By Year
ICLR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ICON PLC
Glance View
ICON PLC is a contract research organization that helps drugmakers and medical device companies run clinical trials. It plans and manages studies, recruits patients, collects and analyzes trial data, and helps customers navigate the regulatory steps needed to test new treatments. The company also offers lab and data services that support drug development from early testing through late-stage trials. Its main customers are pharmaceutical companies, biotech firms, and medical device makers that want to outsource part or all of the development process. ICON earns money by charging for study management, monitoring, data handling, laboratory work, and related services under client contracts. In practice, it acts as an outside partner that helps customers move products through the long, expensive process of proving safety and effectiveness. What makes ICON's business different is its role in the middle of the healthcare development chain. It does not sell medicines itself; instead, it sells specialized expertise, trial infrastructure, and scientific services that many life-science companies need but do not want to build in-house. That makes ICON a service provider tied to the steady demand for drug development and clinical testing.